selegiline Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| monoamine oxydase (MAO)-inhibitors type B | 2429 | 14611-51-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 5 | mg | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 4.40 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 0.10 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.89 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 1.90 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 20 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.13 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.30 hours | Lombardo F, Berellini G, Obach RS |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| June 5, 1989 | FDA | SOMERSET |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Application site erythema | 238.43 | 45.47 | 37 | 271 | 1243 | 2356534 |
| Application site rash | 232.61 | 45.47 | 33 | 275 | 586 | 2357191 |
| Application site pruritus | 145.18 | 45.47 | 23 | 285 | 863 | 2356914 |
| Application site reaction | 94.49 | 45.47 | 14 | 294 | 329 | 2357448 |
| Application site urticaria | 93.19 | 45.47 | 12 | 296 | 94 | 2357683 |
| Application site irritation | 75.02 | 45.47 | 12 | 296 | 470 | 2357307 |
| Dyskinesia | 52.56 | 45.47 | 13 | 295 | 4776 | 2353001 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Gambling disorder | 112.62 | 74.90 | 17 | 201 | 393 | 1746170 |
| Dopamine dysregulation syndrome | 106.67 | 74.90 | 14 | 204 | 110 | 1746453 |
| Hypersexuality | 99.13 | 74.90 | 15 | 203 | 351 | 1746212 |
| Application site rash | 87.89 | 74.90 | 13 | 205 | 258 | 1746305 |
| Hallucination, visual | 81.32 | 74.90 | 17 | 201 | 2575 | 1743988 |
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N04BD01 | NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Monoamine oxidase B inhibitors |
| FDA EPC | N0000175744 | Monoamine Oxidase Inhibitor |
| FDA EPC | N0000175762 | Monoamine Oxidase Type B Inhibitor |
| FDA MoA | N0000175761 | Monoamine Oxidase-B Inhibitors |
| MeSH PA | D018726 | Anti-Dyskinesia Agents |
| MeSH PA | D000928 | Antidepressive Agents |
| MeSH PA | D000978 | Antiparkinson Agents |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
| MeSH PA | D018696 | Neuroprotective Agents |
| MeSH PA | D020011 | Protective Agents |
| MeSH PA | D011619 | Psychotropic Drugs |
Drug Use (View source of the data)
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Parkinson's disease | indication | 49049000 | DOID:14330 |
| Major depressive disorder | indication | 370143000 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Bipolar disorder | contraindication | 13746004 | DOID:3312 |
| Orthostatic hypotension | contraindication | 28651003 | |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Psychotic disorder | contraindication | 69322001 | |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Tardive dyskinesia | contraindication | 102449007 | |
| Angina pectoris | contraindication | 194828000 | |
| Mania | contraindication | 231494001 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Pheochromocytoma | contraindication | 302835009 | |
| Malignant melanoma | contraindication | 372244006 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 7.6 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | Ki | 7.26 | CHEMBL | CHEMBL | |||
| Alpha-2B adrenergic receptor | GPCR | Ki | 6.76 | DRUG MATRIX | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 5.04 | CHEMBL | |||||
| Alpha-2A adrenergic receptor | GPCR | Ki | 6.17 | DRUG MATRIX | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 4.98 | CHEMBL | |||||
| Amine oxidase [flavin-containing] A | Enzyme | Ki | 5.42 | CHEMBL | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 6.01 | CHEMBL | |||||
| Amine oxidase [flavin-containing] B | Enzyme | Ki | 5.87 | CHEMBL | |||||
| Monoamine oxidase | Enzyme | IC50 | 7.89 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4019929 | VUID |
| N0000148014 | NUI |
| C0036579 | UMLSCUI |
| D00785 | KEGG_DRUG |
| 2K1V7GP655 | UNII |
| 4436 | INN_ID |
| 14611-52-0 | SECONDARY_CAS_RN |
| 108466000 | SNOMEDCT_US |
| 4019929 | VANDF |
| 21238 | MMSL |
| 9639 | RXNORM |
| 372497003 | SNOMEDCT_US |
| d00976 | MMSL |
| 004599 | NDDF |
| 26757 | PUBCHEM_CID |
| CHEBI:50217 | CHEBI |
| CHEMBL972 | ChEMBL_ID |
| DB01037 | DRUGBANK_ID |
| CHEMBL1200904 | ChEMBL_ID |
| D012642 | MESH_DESCRIPTOR_UI |
| 6639 | IUPHAR_LIGAND_ID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| ZELAPAR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0187-0453 | TABLET, ORALLY DISINTEGRATING | 1.25 mg | ORAL | NDA | 17 sections |
| Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16571-659 | CAPSULE | 5 mg | ORAL | ANDA | 11 sections |
| EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-900 | PATCH | 6 mg | TRANSDERMAL | NDA | 22 sections |
| EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-901 | PATCH | 9 mg | TRANSDERMAL | NDA | 22 sections |
| EMSAM | HUMAN PRESCRIPTION DRUG LABEL | 1 | 49502-902 | PATCH | 12 mg | TRANSDERMAL | NDA | 22 sections |
| SELEGILINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-019 | CAPSULE | 5 mg | ORAL | ANDA | 11 sections |
| Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-176 | TABLET | 5 mg | ORAL | ANDA | 11 sections |
| SELEGILINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-0055 | CAPSULE | 5 mg | ORAL | ANDA | 11 sections |
| Selegiline Hydrochloride | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-3438 | TABLET | 5 mg | ORAL | ANDA | 11 sections |
| SELEGILINE HYDROCHLORIDE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-2649 | CAPSULE | 5 mg | ORAL | ANDA | 11 sections |